Brief: Moleculin Receives Institutional Review Board Approval For MIRACLE Phase 3 Pivotal Trial Of Annamycin In Combination With Cytarabine For The Treatment Of R/R Acute Myeloid Leukemia (AML)
12/11/2024 13:14
Nov 12 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN RECEIVES INSTITUTIONAL REVIEW BOARD APPROVAL FOR
MIRACLE PHASE 3 PIVOTAL TRIAL OF ANNAMYCIN IN COMBINATION WITH
CYTARABINE FOR THE TREATMENT OF R/R ACUTE MYELOID LEUKEMIA (AML)
* MOLECULIN BIOTECH INC - FIRST SUBJECT TREATMENT IN MIRACLE
TRIAL
EXPECTED Q1 2025
Source text: ID:nPn95MNlba
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM